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Abstract
Objective: Dysregulation of microRNAs (miRNAs) plays critical roles in tumor progression. The aim of this study was
to investigate the clinicopathologic and prognostic significance of miR-497 expression in human breast cancer (BC).
Methods: Taqman qRT-PCR assay was performed to detect the expression of microRNA (miR)-497 in 30 pairs of BC
tissues and corresponding noncancerous breast tissues. Additionally, the expression of this miRNA was detected in
another 128 BC tissues and its correlations with clinicopathologic features of patients were analyzed. Kaplan-Meier
analyses were used to assess survival of patients. Univariate and multivariate analyses were performed using the
Cox proportional hazards model to analyze the prognostic significance of miR-497 expression.
Results: Our data indicated that the relative level of miR-497 expression in BC tissues was significantly lower than
that in corresponding noncancerous breast tissues (P = 0.0046). Of 128 BC patients, 74 (57.8%) were placed in the
high-miR-497 group and 54 (42.2%) were placed in the low-miR-497 group. By statistical analyses, low miR-497
expression was observed to be closely correlated with higher differentiation grade, positive HER-2 expression,
higher incidence of lymph node metastasis and advanced clinical stage. Moreover, patients with high miR-497
expression had better 5-year disease-free and overall survival compared with the low miR-497 group (P = 0.0124
and 0.0018, respectively). Univariate and multivariate analyses indicated that low miR-497 expression was an
independent poor prognostic factor for BC patients.
Conclusions: Our data provided the first evidence that downregulation of miR-497 was correlated with BC
progression, and miR-497 might be a potential molecular biomarker for predicting the prognosis of patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2025828761093488
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Introduction
Breast cancer (BC), the top cancer in women both in the
developed and the developing world, has been a leading
cause of death among women in China, with 1.1 million
new cases annually [1]. Although improvements in early
detection and treatment have decreased breast cancer
mortality rates in recent years, prevention and therapy
of breast cancer remain a major public health concern
[2]. China’s breast cancer mortality has doubled over the
past 30 years. BC is a heterogeneous disease with respect
to molecular alteration, cellular composition, and clinical
outcome. Breast carcinogenesis is a multistep process
characterized by genetic and epigenetic alterations that
influence key cellular pathways involved in growth and
development [3]. Therefore, a better understanding of
the molecular mechanisms involved in BC initiation and
progression will likely contribute to providing useful
prognostic biomarker and therapeutic target for BC
therapy.
MiRNAs are a class of small non-coding RNAs (~22 nt)
which are involved in the regulation of gene expression by
inducing mRNA degradation or repressing mRNA transla-
tion [4,5]. Increasing evidence indicates that miRNAs play
critical roles in many human biological and pathological
processes such as growth, apoptosis, development and
tumorigenesis [6-10]. These tumor-related miRNAs func-
tion as tumor suppressors or oncogenes and modulate
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many aspects of carcinogenesis, including cell proliferation,
cell-cycle control, metastasis and angiogenesis [11-13]. Re-
cently, the correlations of dysregulated miRNAs with hu-
man BCs are increasingly reported. By microarray and
Northern blot analyses, Iorio and his colleagues reported
that miRNAs were aberrantly expressed in human breast
cancer and the overall miRNA expression could clearly
separate normal versus cancer tissues, with the most sig-
nificantly deregulated miRNAs being mir-125b, mir-145,
mir-21, and mir-155 [14]. Using a bead-based flow cyto-
metric miRNA expression profiling method, Blenkiron’
et al. identified 133 miRNAs expressed in human breast
tumors, which could be used to classify breast cancer into
prognostic molecular subtypes [15]. Lerebours’ et al.
showed that a 5-miRNA signature comprising miR-421,
miR-486, miR-503, miR-720 and miR-1303 was shown to
be predictive for inflammatory BC phenotype with an over-
all accuracy of 89% [16]. These data clearly indicate that
specific miRNA expression patterns are associated with
the biological and clinical properties of human BCs. How-
ever, there have been a limited number of studies on the
potential of miRNAs used for prognostic biomarkers and
therapeutic molecular targets in BC. Here, the focus is on
miR-497, which has been reported to be downregulated in
a variety of malignant tumors, including cervical cancer,
colorectal cancer, and prostate cancer [17-19]. By analysis
of the genome-wide expression profiling of miRNAs, Yan
and his colleagues showed that seven miRNAs of hsa-miR-
497, hsa-miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140,
hsa-miR-127 and hsa-miR-30a-3p were significantly down-
regulated in BC [20]. Additionally, Shen’ et al. reported
that miR-497 could induce apoptosis of breast cancer cells
by targeting Bcl-w [21]. However, the prognostic signifi-
cance of miR-497 in BC is not fully understood.
In the present study, qRT-PCR assay was performed
to detect the expression of miR-497 in BC and corre-
sponding noncancerous breast tissues. Moreover, the
correlations of miR-497 expression with clinicopathologic
features of BC patients were statistically analyzed. Finally,
we determined the potential role of miR-497 in BC prog-
nostic prediction. Our data showed that miR-497 was
significantly downregulated in BC tissues and could be
served as a potential molecular biomarker for the predic-
tion of poor prognosis.
Methods and materials
Patients and tissue samples
A total of 128 BC tissues, 30 paired BC and correspond-
ing noncancerous breast tissues were collected directly
from surgery after removal of the necessary amount of tis-
sue for routine pathology examination at the Department
of Pathology, Jinling or Xijing Hospital between 2003 and
2005. The tissues were immediately frozen in liquid nitro-
gen after surgical removal and stored at −80°C until use.
None of the patients recruited in this study had undergone
preoperative chemotherapy or radiotherapy. The charac-
teristics of patients were shown in Table 1. Informed writ-
ten consent was obtained from all patients. The tumors
were frozen at −80°C in a guanidinium thiocyanate
solution. The Chinese Medical Association Society of
Medicine’s Ethics Committee approved all aspects of this
study in accordance with the Helsinki Declaration.
Extraction of total RNA
Total RNA isolation from tissues was performed using
mirVana miRNA Isolation Kit (Applied Biosystems/
Ambion, Austin, TX, USA) according to the methods
described previously [22]. RNA concentrations were
measured using the SPECTRAmax microplate spectro-
photometer (Molecular Devices Corp).
Table 1 Correlations of miR-497 expression with
clinicopathologic features of BC patients
miR-497 expression


























I + II 43 19
III 31 35
*Statistically significant difference (P < 0.05). ER estrogen receptor;
PR progesterone receptor, HER-2 c-erbB-2.
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Taqman quantitative reverse transcription (qRT)-PCR
detection of miR-497 expression
The cDNA was synthesized from 5 ng of total RNA by
using the Taqman miRNA reverse transcription kit
(Applied Biosystems, Foster City, CA), and the expression
levels of miR-497 were quantified by using miRNA-
specific TaqMan MiRNA Assay Kit (Applied Biosystems).
qRT-PCR was performed by using the Applied Biosystems
7500 Sequence Detection system. The expression of
miRNA was defined based on the threshold cycle
(Ct), and relative expression levels were calculated as
2-[(Ct of miR-497)-(Ct of U6)] after normalization with ref-
erence to expression of U6 small nuclear RNA.
Statistical analysis
All statistical analyses were carried out using the SPSS
17.0 software package (SPSS, Chicago, IL, USA). The
data were presented as the mean ± SD. The Chi-squared
test was used to investigate the significance of miR-497
expression as correlated with clinicopathologic features
in BC. Disease-free and overall survival curves were
plotted using the Kaplan-Meier method and were evalu-
ated for the statistical significance using a log-rank test.
The significance of different variables with respect to
survival was analyzed using the univariate and multivari-
ate Cox proportional hazards model. Differences were
considered statistically significant when P < 0.05.
Results
MiR-497 was remarkably downregulated in human BC
tissues
Taqman qRT-PCR assay was performed to detect the ex-
pression of miR-497 in 30 pairs of BC and corresponding
noncancerous breast tissues. The expression of miR-497
in 26 cases of BC tissues was downregulated in compari-
son with that in corresponding noncancerous breast
tissues, but the expression of miR-497 was upregu-
lated in only 4 cases of BC tissues (Figure 1A). It was
shown that the mean expression level of miR-497 in
BC tissues (mean ± SD: 1.23 ± 0.63) was remarkably
lower than that in noncancerous breast tissues (mean ±
SD: 2.89 ± 0.34; P = 0.0046; Figure 1B).
Correlations of miR-497 expression with clinicopathologic
features of BC patients
To further investigate the correlations of miR-497
with various clinicopathologic features of BC patients,
the relative expression of miR-497 was determined in
another 128 cases of BC tissue samples. The median
value of miR-145 in all BC tissues was 1.46 and used
as a cutoff value, and all patients were divided into
two groups: high-miR-497 expression group (≥1.46; n =
74; mean ± SD: 2.04 ± 0.38) and low-miR-497 expres-
sion group (<1.46; n = 54; mean ± SD: 0.45 ± 0.28).
Then, the correlations of miR-497 expression with
clinicopathologic features of patients were statistically
analyzed. As shown in Table 1, low miR-497 expres-
sion was observed to be closely correlated with higher
differentiation grade, positive HER-2 expression, higher
incidence of lymph node metastasis and advanced clin-
ical stage (P = 0.005, 0.024, 0.001 and 0.010, respect-
ively). However, there were no significant correlations
between miR-497 expression and other clinicopatho-
logic factors including age, tumor size, histological type,
ER and PR status (P = 0.204, 0.777, 0.078, 0.590 and 0.598,
respectively).
Correlations of miR-497 expression with disease-free
survival (DFS) and overall survival (OS) of BC patients
To further investigate the correlation of miR-497 expres-
sion with survival of BC patients, Kaplan-Meier analyses
were performed. As shown in Figure 2A, the 5-year DFS
of low-miR-497 expression group (60.4%) was signifi-
cantly shorter than that of high-miR-497 expression
group (81.2%; P = 0.0124). Moreover, the 5-year OS of
low-miR-497 expression group (57.3%) was significantly
shorter than that of high-miR-497 expression group
(71.2%; P = 0.0018) (Figure 2B). These results indicated
that downregulation of miR-497 might be correlated
with poor survival of BC patients.
Univariate and multivariate determination of prognostic
factors in BC patients
Next, univariate analyses were performed to evaluate the
expression of miR-497 and other clinicopathologic fea-
tures on prognosis of BC patients. As shown in Table 2,
it was observed that miR-497 expression, along with age,
tumor size, differentiation grade, histological type, ER
status, PR status, HER status, lymph node metastasis
and clinical stage, was responsible for efficacy of surgical
treatment in BC patient, by indicating that status of
miR-497 expression was significantly correlated with
DFS (P = 0.005) and OS (P = 0.036) of BC patients. Fur-
thermore, multivariate analyses were performed to
evaluate those clinicopathogic features significant in uni-
variate analyses (tumor size, differentiation grade, lymph
node metastasis, clinical stage and status of miR-497 ex-
pression). It was shown that miR-497 expression was an
independent molecular biomarker for the predicting of
DFS (HR: 1.535, 95% CI: 1.127-2.337, P = 0.016) and OS
(HR: 2.123, 95% CI: 1.836-3.015, P = 0.008) in BC pa-
tients (Table 3).
Discussion
As different cancer therapies are effective in different sub-
groups of patients, there is a tremendous need for novel
predictive and prognostic markers to improve the out-
comes of cancer patients [23]. BC is a group of
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heterogeneous diseases that show various biological and
clinical characteristics. Patient management is currently
based on easily identifiable clinical and pathological char-
acteristics, which only partially reflect disease heterogen-
eity. Many principal factors, such as patient age, status of
axillar lymph nodes, tumor size, histological traits, status
of hormonal receptors and HER2, have been used for the
prediction of the prognosis of BC patients for many years
[24,25], but their roles in determining the individual risk
level of the patient are quite limited. Therefore, it is still
needed to exploit clinically useful, readily available prog-
nostic markers in the management of BC.
MiRNAs, important regulators of mRNA and protein
expression, are emerging as important modulators of
essential biological functions, including cellular develop-
ment, apoptosis, metabolism and oncogenesis [26]. It is
estimated that miRNAs may regulate up to a third of the
human genome. They also represent a novel biological
entity with potential value as tumour biomarkers, which
can improve diagnosis, prognosis, and monitoring of
treatment response for human cancers [27,28]. Applica-
tion of the potential role of miRNAs as molecular bio-
markers in human cancer is increasingly supported by
the large number of studies conducted in different can-
cers, including BC [29,30]. Tang’ et al. reported that high
miR-27a expression was associated with poor overall
survival in patients with breast cancer, suggesting that
miR-27a could be a valuable marker of breast cancer
Figure 2 Kaplan-Meier survival curves of BC patients. A. The 5-year DFS of BC patients with high miR-497 expression was significantly higher
than that of those patients with low miR-497 expression (P = 0.0124). B. The 5-year OS of BC patients with high miR-497 expression was
significantly higher than that of those patients with low miR-497 expression (P = 0.0018). The P-value was calculated using the log-rank test
between patients with high- and low-fold changes.
Figure 1 Taqman qRT-PCR detection of relative miR-497 expression in tissue samples. A. qRT-PCR was performed to respectively detect the
relative miR-497 expression in 30 pairs of BC and corresponding noncancerous breast tissues. B. The mean expression level of miR-497 in BC tissues
was significantly lower than that in corresponding noncancerous breast tissues (P = 0.0046). U6 snRNA was used as an internal control. Each assay was
performed at least in triplicate. Corresponding P values analyzed by t-tests are indicated. T: BC tissues; N: noncancerous breast tissues.
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progression [31]. By a meta-analysis, Hong’ et al. indi-
cated that high expression of miR-210 could predict
poor survival in patients with breast cancer [32]. By
screening the expression levels of 754 human miRs using
miR arrays in 16 breast tumor samples from 8 cases with
local recurrence and 8 cases without local recurrence,
Zhou and his colleagues reported that microRNA-9
could be used as a potential biomarker for breast cancer
local recurrence and tumor estrogen receptor status
[33]. As the stability of miRs and their detection in cir-
culation, the miRNAs in body fluids, such as serum and
plasma, open up the possibility of using them as nonin-
vasive biomarkers in breast cancer [34,35]. MiR-497,
identified from the microRNA cluster site at chromo-
some 17p13.1, has been reported to function as a tumor
suppressor in a variety of human cancers, including non-
small cell lung cancer, hepatocelluar cancer, neroblastoma,
colorectal cancer and breast cancer [18,21,36-38]. Mean-
while, it was also reported that miR-497 could modulate
multidrug resistance of human cancer cell lines by target-
ing Bcl-2 [39]. In human cervical cancer, low miR-497 ex-
pression appeared to be an unfavorable prognostic factor
for patients [17]. By analysis of the expression of 319
microRNAs in 9 primary human male breast tumors and
in epithelial cells from 15 male gynecomastia specimens,
Lehmann and his colleagues showed that miR-145 and
miR-497 were identified as most prominently down-
regulated in male BC [40]. However, the status of miR-497
expression in female BC and its prognostic roles are un-
clear. Thus, the aim of this study was to investigate the
correlations of miR-497 expression with clinicopathologic
features and prognosis of BC patients.
Here, we first detect the expression of miR-497 in 30
pairs of BC and corresponding noncancerous breast
tissues, and showed that the relative expression level of
miR-497 in BC was significantly lower than that in non-
cancerous breast tissues. Then, we detected the expres-
sion of miR-497 in another 128 cases of BC tissues and
analyzed its clinicopathologic and prognostic significance.
Our results indicated that status of miR-497 expression in
tissues was significantly correlated with tissue differenti-
ation grade, HER-2 status, incidence of lymph node me-
tastasis and clinical stage of BC patients. It was observed
that patients with low miR-497 expression showed poorer
differentiation grade, higher incidence of lymph node
metastasis and advanced clinical stage, suggesting that
downregulation of miR-497 played an important role in
BC progression. Interestingly, low miR-497 expression
was found to be correlated with positive HER-2 expres-
sion. In previous study, type I insulin-like growth factor
receptor (IGF-1R) was identified as a functional and direct
target of miR-497 in colorectal cancer and cervical cancer
Table 2 Univariate analyses of different prognostic factors in BC patients
Disease-free survival Overall survival
Variables HR (95% CI) P-value HR (95% CI) P-value
Age (years) 1.341 (0.607-1.711) 0.316 1.503 (0.733-2.012) 0.618
Tumor size (cm) 2.278 (1.566-2.791) 0.008* 1.808 (1.127-2.443) 0.016*
Differentiation grade 2.334 (1.789-2.882) 0.022* 2.055 (1.726-3.404) 0.001*
Histological type 0.802 (0.477-1.682) 0.358 1.022 (0.799-1.501) 0.207
ER status 1.563 (0.815-1.921) 0.188 0.865 (0.699-1.118) 0.295
PR status 0.855 (0.429-1.277) 0.098 1.510 (0.719-2.121) 0.411
HER-2 status 1.777 (0.892-1.954) 0.301 1.221 (0.669-1.443) 0.189
Lymph node metastasis 3.122 (1.778-3.828) 0.017* 2.011 (1.548-2.817) 0.038*
Clinical stage 1.718 (1.150-2.203) 0.008* 1.823 (1.199-2.458) 0.014*
MiR-497 expression 2.340 (1.782-2.695) 0.005* 1.504 (1.285-1.914) 0.036*
*P < 0.05. Abbreviations: HR hazard ratio, 95% CI, 95% confidence interval, ER estrogen receptor, PR progesterone receptor, HER-2 c-erbB-2.
Table 3 Mulivariate analyses of different prognostic factors in BC patients
Disease-free survival Overall survival
Variables HR (95% CI) P-value HR (95% CI) P-value
Tumor size (cm) 1.660 (0.875-1.914) 0.115 0.707 (0.680-1.188) 0.073
Differentiation grade 1.146 (0.794-1.326) 0.204 1.522 (0.891-1.927) 0.163
Lymph node metastasis 2.102 (1.377-2.456) 0.009* 1.749 (1.087-2.514) 0.011*
Clinical stage 3.071 (2.318-3.549) 0.021* 2.362 (1.693-2.720) 0.037*
MiR-497 expression 1.535 (1.127-2.337) 0.016* 2.123 (1.836-3.015) 0.008*
*P < 0.05. Abbreviations: HR hazard ratio, 95% CI 95% confidence interval.
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[17,18], and downregulation of miR-497 could lead to the
overexpression of IGF-1R, which leads to malignant trans-
formation and tumor development [41]. The IGF/IGF-1R
pathway has also been shown to have extensive cross-talk
with epidermal growth factor receptor (EGFR), and hu-
man epidermal growth factor receptor 2 (HER-2) signaling
pathways [42]. Thus, whether downregulation of miR-497
might lead to the activation of HER-2 by inducing upregu-
lation of IGF-1R in human BC is unclear and remains to
be elucidated in future studies. Then, we analyzed the cor-
relation of miR-497 expression with prognosis of BC pa-
tients, and found that patients with high miR-497
expression showed better DFS and OS than those with
low miR-497 expression. More importantly, both the uni-
variate and multivariate survival analyses demonstrated
that low miR-497 expression was correlated with shorter
OS and DFS in BC, which was also consistent with the
prognostic significance of miR-497 in other human malig-
nancies, such as cervical cancer and neuroblastoma. These
results indicated that miR-497 might be an important
modulator involved in BC development.
Taken together, the current study indicates that miR-
497 is downregulated in BC tissues and might be an
independent molecular biomarker for predicting the
prognosis of BC patients. Of course, this study has sev-
eral limits. First, as the number of patients in this study
is smaller, a larger case population is needed to confirm
the prognostic value of miR-497 expression in BC. Sec-
ond, as formalin-fixed, paraffin-embedded tissues display
(FFPE) degradation of nucleic acids if compared to fresh
materials, the HOPE-technique with laser microdissec-
tion represents a novel tool for future tissue-based stud-
ies described recently [43]. Finally, further investigation
of the cell biology of miR-497 and its potential as a
therapeutic target in BC are clearly warranted.
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